Triển vọng mới trong điều trị các bệnh tích trữ lysosome

Kaye EM. Lysosomal storage diseases. Curr Treat Options Neurol 2000; 3: 249–56 Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249–54 Brady RO. Gaucher’s disease: past, present and future. Baillieres Clin Haematol 1997; 10: 621–34 Cox TM, Schofield JP. Gaucher’s disease: clinical features and natural history. Baillieres Clin Haematol 1997; 10: 657–89 Barton NW, Brady RO, Dambrosia JM, et al. Replacement ther-apy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 1991; 324: 1464–70 Altarescu G, Schiffmann R, Parker CC, et al. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis 2000; 26: 285–90 Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J Pediatr 2001; 138: 539–47 Cohen IJ, Katz K, Kornreich L, et al. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis 1998; 24: 296–302 Patterson MC, Horowitz M, Abel RB, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher’s disease. Neurology 1993; 43: 1993–7 Vellodi A, Bembi B, de Villemeur TB, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001; 24: 319–27 Erikson A, Bembi B, Schiffmann R. Neuronopathic forms of Gaucher’s disease. Baillieres Clin Haematol 1997; 10: 711–23 Elstein D, Klutstein MW, Lahad A, et al. Echocardiographic assessment of pulmonary hypertension in Gaucher’s disease. Lancet 1998; 351: 1544–6 Goitein O, Elstein D, Abrahamov A, et al. Lung involvement and enzyme replacement therapy in Gaucher’s disease. QJM 2001; 94: 407–15 Elstein D, Abrahamov A, Hadas-Halpern I, et al. Withdrawal of enzyme replacement therapy in Gaucher’s disease. Br J Haematol 2000; 110: 488–92 Elstein D, Abrahamov A, Hadas-Halpern I, et al. Recommendations for diagnosis, evaluation, and monitoring of patients with Gaucher disease. Arch Intern Med 1999; 159: 1254–5 Samuel R, Katz K, Papapoulos SE, et al. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher’s disease. Pediatrics 1994; 94: 385–9 Wenstrup RJ, Bailey L, Grabowski GA, et al. Alendronate disodium improves bone mineral density in adults receiving enzyme replacement therapy (ERT) for Gaucher disease. Am J Hum Genet 2001; 69: 674 Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA 2000; 284: 2771–5 Brady R, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl J Med 1967; 276: 1163–7 Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A Deficiency: Fabry Disease. In: Charles R, Scriver, Arthur L, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001: 3733–74 Branton MH, Schiffmann R, Sabnis SG, et al. Quantitative natural history of Fabry renal disease: influence of a-galactosidase A activity and genetic mutations on clinical course. Medicine. In press 2002 Schiffmann R, Murray GJ, Treco D, et al. Infusion of α-galactosidase A reduces tissue globotriosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000; 97: 365–70 Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743–9 Moore D, Scott, LJC, Gladwin MT, et al. Regional cerebral hyper-perfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001. In press Eng CM, Banikazemi M, Gordon RE, et al. A phase ½ clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68: 711–22 Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A -replacement therapy in Fabry’s disease. N Engl J Med 2001; 345: 9–16 Elleder M, Bradova V, Smid F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease: report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch APathol Anat Histopathol 1990; 417: 449–55 Van den Hout H, Reuser AJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000; 356: 397–8 Van den Hout JM, Reuser AJ, de Klerk JB, et al. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001; 24: 266–74 Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001; 3: 132–8 Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344: 182–8 Byers S, Nuttall JD, Crawley AC, et al. Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Bone 1997; 21: 425–31 Daly TM, Vogler C, Levy B, et al. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci U S A 1999; 96: 2296–300 Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 1999; 12: 167–76 Ringden O, Groth CG, Erikson A, et al. Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplantation 1995; 59: 864–70 Herskhovitz E, Young E, Rainer J, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): longterm follow-up. J Inherit Metab Dis 1999; 22: 50–62 Lee V, Li CK, Shing MM, et al. Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant 2000; 26: 455–8 Peters C, Krivit W. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome). Bone Marrow Transplant 2000; 25: 1097–9 Krivit W, Shapiro EG, Peters C, et al. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl J Med 1998; 338: 1119–26 Lachmann RH, Platt FM. Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin Investig Drugs 2001; 10: 455–66 Platt FM, Neises GR, Reinkensmeier G, et al. Prevention of lysosomal storage in Tay-Sachs mice treated with Nbutyldeoxynojirimycin. Science 1997; 276: 428–31 Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481–5 Yamashita T, Wada R, Sasaki T, et al. A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A 1999; 96: 9142–7 Brigande JV, Platt FM, Seyfried TN. Inhibition of glycosphingolipid biosynthesis does not impair growth or morphogenesis of the postimplantation mouse embryo. J Neurochem 1998; 70: 871–82 Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A 1999; 96: 6388–93 Jeyakumar M, Norflus F, Tifft CJ, et al. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 2001; 97: 327–9 Platt FM, Jeyakumar M, Andersson U, et al. 2001. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 2001; 24: 275–90 Andersson U, Butters TD, Dwek RA, et al. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 2000; 59: 821–9 Abe A, Gregory S, Lee L, et al. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 2000; 105: 1563–71 Abe A, Wild SR, Lee WL, et al. Agents for the treatment of glycosphingolipid storage disorders. Curr Drug Metab 2001; 2: 331–8 Fan JQ, Ishii S, Asano N, et al. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999; 5: 112–5 Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry’s disease with galactose-infusion therapy. N Engl J Med 2001; 345: 25–32 Zhang Z, Butler JD, Levin SW, et al. Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood. Nat Med 2001; 7: 478–84 Jung SC, Han IP, Limaye A, et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci U S A 2001; 98: 2676–81 Frisella WA, O’Connor LH, Vogler CA, et al. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol Ther 2001; 3: 351–8 Kosuga M, Sasaki K, Tanabe A, et al. Engraftment of genetically engineered amniotic epithelial cells corrects lysosomal storage in multiple areas of the brain in mucopolysaccharidosis type VII mice. Mol Ther 2001; 3: 139–48 Takenaka T, Qin G, Brady RO, et al. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. Hum Gene Ther 1999; 10: 1931–9 Consiglio A, Quattrini A, Martino S, et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med 2001; 7: 310–6 Huang MM, Wong A, Yu X, et al. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts. Gene Ther 1997; 4: 1150–9 Barranger JA, Rice EO, Dunigan J, et al. Gaucher’s disease: studies of gene transfer to haematopoietic cells. Baillieres Clin Haematol 1997; 10: 765–78 Dunbar CE, Kohn DB, Schiffmann R, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 1998; 9: 2629–40 Phase I/II study of retroviral-mediated transfer of iduronate-2-sulfatase gene into lymphocytes of patients with mucopolysaccharidosis II (mild Hunter Syndrome) [online]. Available from URL: http://clinicaltrials.gov/search/term=mucopolysaccharidoses [Accessed 2002 March 10] Zirzow GC, Sanchez OA, Murray GJ, et al. Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain. Neurochem Res 1999; 24: 301–5 Morris MC, Depollier J, Mery J, et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173–6 Wysocki PJ, Grabarczyk P, Mackiewicz A. Recent developments in retroviral gene delivery systems. Expert Opin Biol Ther 2001; 1: 911–3